GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intelgenx Technologies Corp (OTCPK:IGXT) » Definitions » Cyclically Adjusted PS Ratio

Intelgenx Technologies (Intelgenx Technologies) Cyclically Adjusted PS Ratio : 4.18 (As of May. 27, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Intelgenx Technologies Cyclically Adjusted PS Ratio?

As of today (2024-05-27), Intelgenx Technologies's current share price is $0.167. Intelgenx Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.04. Intelgenx Technologies's Cyclically Adjusted PS Ratio for today is 4.18.

The historical rank and industry rank for Intelgenx Technologies's Cyclically Adjusted PS Ratio or its related term are showing as below:

IGXT' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.75   Med: 12.5   Max: 25.8
Current: 4.03

During the past years, Intelgenx Technologies's highest Cyclically Adjusted PS Ratio was 25.80. The lowest was 2.75. And the median was 12.50.

IGXT's Cyclically Adjusted PS Ratio is ranked better than
57.99% of 507 companies
in the Biotechnology industry
Industry Median: 5.5 vs IGXT: 4.03

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Intelgenx Technologies's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.001. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.04 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Intelgenx Technologies Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Intelgenx Technologies's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelgenx Technologies Cyclically Adjusted PS Ratio Chart

Intelgenx Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.73 5.25 8.14 4.72 3.33

Intelgenx Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.27 4.60 3.39 3.33 4.25

Competitive Comparison of Intelgenx Technologies's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Intelgenx Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intelgenx Technologies's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intelgenx Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Intelgenx Technologies's Cyclically Adjusted PS Ratio falls into.



Intelgenx Technologies Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Intelgenx Technologies's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.167/0.04
=4.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intelgenx Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Intelgenx Technologies's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.001/126.2576*126.2576
=0.001

Current CPI (Mar. 2024) = 126.2576.

Intelgenx Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.003 99.473 0.004
201409 0.007 99.394 0.009
201412 0.013 98.367 0.017
201503 0.010 99.789 0.013
201506 0.009 100.500 0.011
201509 0.037 100.421 0.047
201512 0.022 99.947 0.028
201603 0.013 101.054 0.016
201606 0.011 102.002 0.014
201609 0.025 101.765 0.031
201612 0.030 101.449 0.037
201703 0.021 102.634 0.026
201706 0.017 103.029 0.021
201709 0.019 103.345 0.023
201712 0.022 103.345 0.027
201803 0.004 105.004 0.005
201806 0.003 105.557 0.004
201809 0.010 105.636 0.012
201812 0.007 105.399 0.008
201903 0.004 106.979 0.005
201906 0.002 107.690 0.002
201909 0.001 107.611 0.001
201912 0.001 107.769 0.001
202003 0.002 107.927 0.002
202006 0.000 108.401 0.000
202009 0.005 108.164 0.006
202012 0.007 108.559 0.008
202103 0.003 110.298 0.003
202106 0.001 111.720 0.001
202109 0.004 112.905 0.004
202112 0.003 113.774 0.003
202203 0.002 117.646 0.002
202206 0.003 120.806 0.003
202209 0.001 120.648 0.001
202212 0.001 120.964 0.001
202303 0.001 122.702 0.001
202306 0.001 124.203 0.001
202309 0.002 125.230 0.002
202312 0.002 125.072 0.002
202403 0.001 126.258 0.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Intelgenx Technologies  (OTCPK:IGXT) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Intelgenx Technologies Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Intelgenx Technologies's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Intelgenx Technologies (Intelgenx Technologies) Business Description

Traded in Other Exchanges
Address
6420 Abrams, Ville Saint Laurent, QC, CAN, H4S 1Y2
Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. Intelegenx focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer and manufacturing scale-up, and commercial manufacturing. Its geographical segments are Europe, Canada, and United States.
Executives
Atai Life Sciences Ag 10 percent owner KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Atai Life Sciences N.v. 10 percent owner 524 BROADWAY, NEW YORK NY 10013
Karen Kalayajian officer: VP, Finance&Admin - Subsidiary 4896 RUE EDOUARD-BRUNETTE, LAVAL A8 H7T 0J4
Dwight Gorham officer: CEO 15B BARKLEY ST, ARNPRIOR A6 K7S 3G8
David Kideckel officer: SVP, Corp. Dev&SA - Subsidiary 23 PEVERIL HILL SOUTH, TORONTO, ON A6 M6C 3A7
Horst G Zerbe 10 percent owner, officer: Chief Executive Officer 714 MAIN ROAD, HUDSON A8 JOP1H0
Andre Godin officer: CFO 440 DES CARMANTINES, LAVAL A8 H7X 0B6
Tommy Kenny officer: VP IP,Lgl Affairs - Subsidiary 88 CH. DES SAULES, ST-ADOLPHE D' HOWARD A8 J0T 2B0
Dana Matzen officer: VP Business+Corp. Development 4771 RUE SHERBROOKE O., WESTMOUNT A8 H3Z1G5
Ingrid Zerbe 10 percent owner, officer: Corporate Secretary 714 MAIN ROAD, HUDSON A8 J0P1H0
Rodolphe Obeid officer: Vice President, Operations 4779 RUE VILLERET, PIERREFOND A8 H9K1P6
Bernard Boudreau director 2 TURNMILL DR., HALIFAX A5 B3M4H2
John Edward Durham officer: Vice President Manufacturing 102 MAYFAIR, HUDSON A8 J0P1H0
Mark Nawacki director 118 ARLINGTON AVENUE, WESTMOUNT A8 H3Y2W4
Robert J. Bechard officer: VP Corporate Development 141 EASTON AVENUE, MONTREAL WEST A8 H4X 1L4

Intelgenx Technologies (Intelgenx Technologies) Headlines